327 related articles for article (PubMed ID: 22115704)
1. Comparison of pemetrexed plus cisplatin with other first-line doublets in advanced non-small cell lung cancer (NSCLC): a combined analysis of three phase 3 trials.
Treat J; Scagliotti GV; Peng G; Monberg MJ; Obasaju CK; Socinski MA
Lung Cancer; 2012 May; 76(2):222-7. PubMed ID: 22115704
[TBL] [Abstract][Full Text] [Related]
2. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.
Scagliotti GV; Parikh P; von Pawel J; Biesma B; Vansteenkiste J; Manegold C; Serwatowski P; Gatzemeier U; Digumarti R; Zukin M; Lee JS; Mellemgaard A; Park K; Patil S; Rolski J; Goksel T; de Marinis F; Simms L; Sugarman KP; Gandara D
J Clin Oncol; 2008 Jul; 26(21):3543-51. PubMed ID: 18506025
[TBL] [Abstract][Full Text] [Related]
3. Rationale and design of MILES-3 and MILES-4 studies: two randomized phase 3 trials comparing single-agent chemotherapy versus cisplatin-based doublets in elderly patients with advanced non--small-cell lung cancer.
Gridelli C; Rossi A; Di Maio M; Leo S; Filipazzi V; Favaretto AG; Burgio MA; Cinieri S; Bianco R; Ciardiello F; Cavanna L; Bordonaro R; Costanzo R; Sandomenico C; Gallo C; Perrone F; Morabito A
Clin Lung Cancer; 2014 Mar; 15(2):166-70. PubMed ID: 24418693
[TBL] [Abstract][Full Text] [Related]
4. The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
Scagliotti G; Hanna N; Fossella F; Sugarman K; Blatter J; Peterson P; Simms L; Shepherd FA
Oncologist; 2009 Mar; 14(3):253-63. PubMed ID: 19221167
[TBL] [Abstract][Full Text] [Related]
5. Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung cancer: final survival analysis from a multicentre randomized phase II trial in the East Asia region and a meta-analysis.
Zhang X; Lu J; Xu J; Li H; Wang J; Qin Y; Ma P; Wei L; He J
Respirology; 2013 Jan; 18(1):131-9. PubMed ID: 22882698
[TBL] [Abstract][Full Text] [Related]
6. Non-platinum doublets were as effective as platinum-based doublets for chemotherapy-naïve advanced non-small-cell lung cancer in the era of third-generation agents.
Jiang J; Liang X; Zhou X; Huang R; Chu Z; Zhan Q
J Cancer Res Clin Oncol; 2013 Jan; 139(1):25-38. PubMed ID: 22864816
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer.
Wu YL; Lu S; Cheng Y; Zhou C; Wang M; Qin S; Lu Y; Zhang Y; Zhu Y; Song X; Wang X; Barraclough H; Zhang X; Chi H; Orlando M
Lung Cancer; 2014 Sep; 85(3):401-7. PubMed ID: 25082564
[TBL] [Abstract][Full Text] [Related]
8. Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer.
Syrigos KN; Vansteenkiste J; Parikh P; von Pawel J; Manegold C; Martins RG; Simms L; Sugarman KP; Visseren-Grul C; Scagliotti GV
Ann Oncol; 2010 Mar; 21(3):556-561. PubMed ID: 19828561
[TBL] [Abstract][Full Text] [Related]
9. Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data.
Santana-Davila R; Szabo A; Arce-Lara C; Williams CD; Kelley MJ; Whittle J
J Thorac Oncol; 2014 May; 9(5):702-9. PubMed ID: 24662458
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and resource use of non-small cell lung cancer (NSCLC) patients treated with first-line platinum-based chemotherapy across Europe: FRAME prospective observational study.
Moro-Sibilot D; Smit E; de Castro Carpeño J; Lesniewski-Kmak K; Aerts J; Villatoro R; Kraaij K; Nacerddine K; Dyachkova Y; Smith KT; Taipale K; Girvan AC; Visseren-Grul C; Schnabel PA
Lung Cancer; 2015 May; 88(2):215-22. PubMed ID: 25748103
[TBL] [Abstract][Full Text] [Related]
11. An indirect comparison of bevacizumab plus cisplatin-gemcitabine and cisplatin plus pemetrexed treatment for patients with advanced first-line non-squamous non-small cell lung cancer in East Asia.
Chang JW; Thongprasert S; Wright E; Tsang K; Kim HT; Ahn MJ; Kim JH; Kang JH; Kim SW; Walzer S
Asia Pac J Clin Oncol; 2011 Jun; 7 Suppl 2():13-21. PubMed ID: 21585704
[TBL] [Abstract][Full Text] [Related]
12. Randomized control study of nedaplatin or cisplatin concomitant with other chemotherapy in the treatment of advanced non-small cell lung cancer.
Li CH; Liu MY; Liu W; Li DD; Cai L
Asian Pac J Cancer Prev; 2014; 15(2):731-6. PubMed ID: 24568487
[TBL] [Abstract][Full Text] [Related]
13. Treatment-by-histology interaction analyses in three phase III trials show superiority of pemetrexed in nonsquamous non-small cell lung cancer.
Scagliotti G; Brodowicz T; Shepherd FA; Zielinski C; Vansteenkiste J; Manegold C; Simms L; Fossella F; Sugarman K; Belani CP
J Thorac Oncol; 2011 Jan; 6(1):64-70. PubMed ID: 21119545
[TBL] [Abstract][Full Text] [Related]
14. Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer.
Cohen MH; Justice R; Pazdur R
Oncologist; 2009 Sep; 14(9):930-5. PubMed ID: 19737998
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of cisplatin/pemetrexed versus cisplatin/gemcitabine as first-line treatment in East Asian patients with advanced non-small cell lung cancer: results of an exploratory subgroup analysis of a phase III trial.
Yang CH; Simms L; Park K; Lee JS; Scagliotti G; Orlando M
J Thorac Oncol; 2010 May; 5(5):688-95. PubMed ID: 20150825
[TBL] [Abstract][Full Text] [Related]
16. The role of histology with common first-line regimens for advanced non-small cell lung cancer: a brief report of the retrospective analysis of a three-arm randomized trial.
Scagliotti GV; De Marinis F; Rinaldi M; Crinò L; Gridelli C; Ricci S; Zhao YD; Liepa AM; Peterson P; Tonato M
J Thorac Oncol; 2009 Dec; 4(12):1568-71. PubMed ID: 20009911
[TBL] [Abstract][Full Text] [Related]
17. Survival without toxicity for cisplatin plus pemetrexed versus cisplatin plus gemcitabine in chemonaïve patients with advanced non-small cell lung cancer: a risk-benefit analysis of a large phase III study.
Scagliotti GV; Park K; Patil S; Rolski J; Goksel T; Martins R; Gans SJ; Visseren-Grul C; Peterson P
Eur J Cancer; 2009 Sep; 45(13):2298-303. PubMed ID: 19473833
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
[TBL] [Abstract][Full Text] [Related]
19. Safety and resource utilization by non-small cell lung cancer histology: results from the randomized phase III study of pemetrexed plus cisplatin versus gemcitabine plus cisplatin in chemonaïve patients with advanced non-small cell lung cancer.
Novello S; Pimentel FL; Douillard JY; O'Brien M; von Pawel J; Eckardt J; Liepa AM; Simms L; Visseren-Grul C; Paz-Ares L
J Thorac Oncol; 2010 Oct; 5(10):1602-8. PubMed ID: 20808252
[TBL] [Abstract][Full Text] [Related]
20. A landmark point analysis with cytotoxic agents for advanced NSCLC.
Yamamoto N; Nambu Y; Fujimoto T; Koshiji M
J Thorac Oncol; 2009 Jun; 4(6):697-701. PubMed ID: 19318995
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]